HIF1A and COVID-19: In sum, these findings suggest that HIF1A upregulation outlasts acute SARS-CoV-2 infection despite the absence of clinical symptoms of COVID-19 and absence of previously described transcriptomic dysregulations characteristic of acute COVID-19 such as those related to a cytokine storm or MHC downregulation.